Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
FAIL · Does not pass the screen
53.36 USD
At the last full screen 2026-09-15
Screened 2026-09-15 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 53.36 against the desk's fair-value range, base estimate 74.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price53.36 USD
Fair value74.00
Ethical score70.0/100
Our investment reviews on this name
2026-08-27Read Accumulation60.87-12.3% to today
2026-07-02Read Markdown46.13+15.7% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Enliven Therapeutics, Inc. holds its Markdown at $53.36. The statistical read favours the sellers, held for 25 days.
As held on the ledger · 2026-09-15
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 25 days
Price at the screen
$53.36
Valuation
N/A trailing · -22.82 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.25
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.08%
Below 33%
Interest-bearing debt is just 0.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
76.39%
Below 33%
Interest-bearing cash and securities are 76.4% of assets, above the one-third limit.
Fail
Receivables
20.77%
Below 49%
Money owed to the company is 20.8% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 38.7% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +39% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early cancer drug bets face thin data walls
A clinical stage biotech chasing small molecule inhibitors for cancer feels like funding a lab notebook that might one day become a pill. Enliven sits at that exact point, with its lead candidate still in Phase 1 and zero product revenue to date. We pass because the opportunity rating shows none and the ethical screen returns insufficient data on basic financial ratios.
The numbers underline the gap. Forward P/E sits at negative 22.9 times, profit margins are zero and return on equity is negative 27 percent. Nine analysts still carry a strong buy consensus and a 62 dollar median target above the current 53.20 price, yet those forecasts rest on future trial success that remains unproven.
Risk sits around the complete lack of financial history and ethical metrics, plus the usual binary outcome of early oncology trials. Currency or cyclical exposure does not apply here; instead the absence of any moat rating or ratio coverage leaves the position too thin to assess properly. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ELVN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
2026-07-27Markdown$53.20+15.3%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 15.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
2026-07-18Markdown$46.13+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
2026-07-03Markdown$46.13+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$46.13Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
